Just a moment, the page is loading...
To report an adverse event or product complaint please call 844-4-SAGERX
 

Funding & Giving

Sage supports people and organizations that come together to create positive, lasting change.

Working together, Sage believes we can achieve our mission to pioneer solutions to help deliver life-changing brain health medicines, so every person can thrive. We offer grants and sponsorships to organizations and initiatives aligned with our mission and strategy.

Grants & Sponsorships

Where possible, Sage seeks to support the work of scientists, researchers, and community-based organizations aligned with our mission with select grants, sponsorships, and other funding opportunities. All funding requests must follow Sage's internal policies and procedures, as well as all applicable laws, regulations, and industry codes. Sage will not support requests from organizations that discriminate on the basis of age, political affiliation, race, national origin, ethnicity, gender, disability, sexual orientation or religious beliefs.

The following information provides more context regarding the types of requests Sage will consider funding and is most likely to accept. Please note that Sage will only consider funding and giving requests made through the request forms linked to this site. While we appreciate each request we receive, Sage cannot support every application for funding. All decisions are final.

Disease States

  • Major Depressive Disorder (MDD)
  • Postpartum Depression (PPD)
  • Huntington’s Disease (HD)

Depression Franchise

  • Major Depressive Disorder (MDD)

    • Understanding the burden of MDD and the impact of unmet needs in MDD on patients and their families
    • Advances in the understanding of the pathophysiology of MDD, including but not limited to the potential role of endogenous neuroactive steroids and GABAergic neurotransmission in the expression of MDD symptoms
    • Understanding the clinical implications of suboptimal treatment of MDD
    • Review of evidence of safety and efficacy of new and emerging pharmacotherapies for MDD
  • Postpartum Depression (PPD)

    • Understanding the burden of PPD and the impact of delayed diagnosis and treatment on patient and family outcomes
    • Increasing awareness of optimal approaches for the early identification of PPD and opportunities for improved interdisciplinary care of patients with PPD
    • Advances in the understanding of the pathophysiology of PPD, including but not limited to the potential role of endogenous neuroactive steroids and GABAergic neurotransmission in the expression of PPD symptoms
    • Review of evidence of safety and efficacy of new and emerging pharmacotherapies for PPD

Education for HCPs, including but not limited to the following audiences:

  • Psychiatrists, Psychiatric Nurse Practitioners (NPs), Psychiatric Pharmacists, Psychiatric Physician Associates/Assistants (PAs), and Primary Care Mental Health Specialists (MDD/PPD)
  • Obstetricians/Gynecologists, Maternal Fetal Medicine Specialists, Reproductive Psychiatrists (PPD)
  • General primary care providers including MD/DO, NP, and PAs working in internal medicine or family practice (MDD/PPD)

Format (to support broad, interactive education)

  • US-based grant applications
  • Live education (including symposia at national and regional congresses and profession-specific regional series; in person or virtual) with enduring component as warranted
  • Digital/online asynchronous enduring education
  • Digital/online microlearning modules
  • Print or digital articles

Neuropsychiatry Franchise

  • Huntington's Disease (HD)

    • The hypothesized implications of N-methyl-D-aspartate (NMDA) neuropathology in HD as it relates to cognitive impairment
    • Understanding NMDA receptor hypofunction in the context of overall HD pathophysiology
    • Impact of delayed diagnosis and treatment of early cognitive symptoms in HD
    • Understanding cholesterol dysregulation and the hypothesized role of 24S hydroxycholesterol in HD
    • Review of the current/future treatment landscape for cognitive impairment in HD
    • Impact of early diagnosis of cognitive symptoms in HD in the absence of motor symptoms
    • Increasing external knowledge of the need for revised diagnostic guidelines in HD
    • Review of evidence of safety and efficacy of NMDA positive allosteric modulators for cognitive impairment across various indications

Education for HCPs, including but not limited to the following audiences:

  • Movement Disorder Specialists, Neurologists, Psychiatrists, Clinical Psychologists

Format (to support broad, interactive education)

  • US-based grant applications
  • Live education (including symposia at national and regional congresses and profession-specific regional series; in person or virtual) with enduring component as warranted
  • Digital/online asynchronous enduring education
  • Digital/online microlearning modules
  • Print or digital articles

Educational grant requests must conform to the following:

  • Grant requests must be unsolicited, should have multiple funders, and must not provide nor promise any benefit to Sage.
  • Educational programs, activities, or materials that are designed to promote the institution’s or organization’s bona fide patient or educational services must relate to an area of interest to Sage.
  • Funding amounts must be reasonable for the activities proposed and grant funds must only be used for the expenses described in the grant application and the approval agreement.

Educational grant requests may NOT:

  • Be payable to an individual HCP or physician practice, or companies predominantly owned by a practicing individual HCP or his/her spouse, or the charitable arm thereof.
  • Request use of funding to support conference travel grants or registration fees for HCPs (other than funding of scholarships to permit medical students, residents, fellows or other HCPs in training to attend carefully selected educational conferences without naming the recipient).
  • Be for education that is routine and/or a required part of medical training, e.g. textbooks, journal subscriptions, or preparation materials for Board reviews.
In 2023, grant submissions will be reviewed on a quarterly basis. Below are timeframes for the quarterly reviews and corresponding submission deadlines:
Q1 Grants submission deadline: January 15th
Q1 Grants review: Mid-March
Q2 Grants submission deadline: April 1st
Q2 Grants review: Mid-June
Q3 Grants submission deadline: July 1st
Q3 Grants review: Mid-September
Q4 Grants submission deadline: October 1st
Q4 Grants review: Mid-December

Funding decisions for grants are made through a formal, centralized grant review and decision-making process.

In all cases, Sage notifies applicants of decisions by email. All applications recieve a fair review, and we encourage organizations to reapply for future programs and initiatives.



Apply Now

If you have any questions, please email grants@sagerx.com.

Sponsorship requests:

  • must clearly identify the benefit offered to Sage.
  • must include sponsorship benefits and any amount requested must be reasonable for the activities proposed and consistent with comparable meetings or events.
  • must be made available to multiple organizations, and not just to Sage.

All sponsorship requests will be reviewed on an ongoing basis. Funding decisions for sponsorships are made through a formal, centralized review and decision-making process.

In all cases, Sage notifies applicants of our decision by email. All applications receive a fair review, and we encourage organizations to reapply for future programs and initiatives.



Apply Now

If you have any questions, please email sponsorship@sagerx.com.

Investigator Initiated Research (IIR) Grants

Sage is committed to helping support Investigator Initiated Research (IIR) that furthers scientific and clinical understanding of life-altering brain health disorders. IIR is research that is initiated, sponsored and conducted by an external investigator or institution. IIR requests may include funding, drug supply, or both. Sage’s IIR program is managed by an internal IIR Committee and is governed by Sage’s internal policies and procedures. All decisions are final.

Brexanolone IIR Areas of Interest

  • Women's Health
    • PPD Prophylaxis (History of Depression)
    • Postpartum Psychosis
    • Postpartum Obsessive-Compulsive Disorder (OCD)
    • Antenatal Depression (treatment initiation postpartum day 1 or 2 for antenatal onset of depression)
  • PPD Well-being & Functioning
    • Mother/Family Health-related Quality of Life (HRQoL) and Functioning
    • Child (Well Baby Outcomes)
    • Effects on sleep architecture
  • Other Neuropsychiatric and Neurologic Conditions (e.g., tinnitus, acute Post-traumatic stress disorder, Panic Disorder, COVID-19 infection-related neurological sequelae, involuntary speech disorders, substance abuse disorders, catatonia)
  • Preclinical (e.g. imaging, neuronal remodeling, signaling pathways)


Apply Now

If you have any questions, please email grants@sagerx.com.


Report Adverse Event

If you have an adverse event or product complaint to report, please call 844-4-SAGERX


©2023 Sage Therapeutics, Inc. All rights reserved.
SAGE THERAPEUTICS, ZULRESSO and their respective logos, and SAGE CENTRAL are registered trademarks of Sage Therapeutics, Inc. All other trademarks referenced herein are the property of their respective owners.
MRC-ZUL-00155 10/21